Lifeboat Foundation

By David Glance Director of UWA Centre for Software Practice, University of Western Australia

Pharmaceutical companies typically develop new drugs with thousands of staff and budgets that run into the billions of dollars. One estimate puts the cost of bringing a new drug to market at $2.6 billion with others suggesting that it could be double that cost at $5 billion.

Continue reading “Garage Biotech: New drugs using only a computer, the internet and free online data” »

Interesting approach.

If you’re at all interested in your health, it’s likely you’ve joined the 20 percent of Americans who’ve incorporated fitness trackers into their daily ensemble. From monitoring steps and daily activity to sleep, an ever-growing number of devices are tracking and analyzing our body’s data in an effort to make us better.

But how good is this tracking? Despite noble intentions, the scientific reality is that much of the data these trackers provide is insufficient and inaccurate — and in turn, are not as effective as they promise.

Continue reading “Use Your Brain. Ditch Your Fitness Tracker” »

Today, we’re announcing a new series of workshops and an interagency working group to learn more about the benefits and risks of artificial intelligence.

There is a lot of excitement about artificial intelligence (AI) and how to create computers capable of intelligent behavior. After years of steady but slow progress on making computers “smarter” at everyday tasks, a series of breakthroughs in the research community and industry have recently spurred momentum and investment in the development of this field.

Today’s AI is confined to narrow, specific tasks, and isn’t anything like the general, adaptable intelligence that humans exhibit. Despite this, AI’s influence on the world is growing. The rate of progress we have seen will have broad implications for fields ranging from healthcare to image- and voice-recognition. In healthcare, the President’s Precision Medicine Initiative and the Cancer Moonshot will rely on AI to find patterns in medical data and, ultimately, to help doctors diagnose diseases and suggest treatments to improve patient care and health outcomes.

A groundbreaking trial to see if it is possible to regenerate the brains of dead people, has won approval from health watchdogs.

A biotech company in the US has been granted ethical permission to recruit 20 patients who have been declared clinically dead from a traumatic brain injury, to test whether parts of their central nervous system can be brought back to life.

Scientists will use a combination of therapies, which include injecting the brain with stem cells and a cocktail of peptides, as well as deploying lasers and nerve stimulation techniques which have been shown to bring patients out of comas.

Continue reading “Dead could be brought ‘back to life’ in groundbreaking project” »

Producers say ‘cultured meat’ tastes good and is better for you and the environment.

Silicon Valley’s newest valley member; wonder if Google or eBay will send a “Welcome Basket” to the FDA?

Helmy Eltoukhy’s company is on a roll. The start-up is a leading contender in the crowded field of firms working on “liquid biopsy” tests that aim to be able to tell in a single blood draw whether a person has cancer.

Venture investors are backing Guardant Health to the tune of nearly $200 million. Leading medical centers are testing its technology. And earlier this month, it presented promising data on how well its screening tool, which works by scanning for tiny DNA fragments shed by dying tumor cells, worked on an initial group of 10,000 patients with late-stage cancers.

Continue reading “FDA new sheriff in town in Silicon Valley” »

Russia’s ongoing nuclear fallout challenges.

MUSLYUMOVO, Russia (AP) — At first glance, Gilani Dambaev looks like a healthy 60-year-old man and the river flowing past his rural family home appears pristine. But Dambaev is riddled with diseases that his doctors link to a lifetime’s exposure to excessive radiation, and the Geiger counter beeps loudly as a reporter strolls down to the muddy riverbank.

Some 50 kilometers (30 miles) upstream from Dambaev’s crumbling village lies Mayak, a nuclear complex that has been responsible for at least two of the country’s biggest radioactive accidents. Worse, environmentalists say, is the facility’s decades-old record of using the Arctic-bound waters of the Techa River to dump waste from reprocessing spent nuclear fuel, hundreds of tons of which is imported annually from neighboring nations.

Continue reading “Russia’s nuclear nightmare flows down radioactive river” »

Nice; however, I see also 3D printing along with machine learning being part of any cosmetic procedures and surgeries.

With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes. An overview of machine learning and some of the ways it could contribute to advancements in plastic surgery are presented in a special topic article in the May issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

“Machine learning has the potential to become a powerful tool in plastic surgery, allowing surgeons to harness complex clinical data to help guide key clinical decision-making,” write Dr. Jonathan Kanevsky of McGill University, Montreal, and colleagues. They highlight some key areas in which machine learning and “Big Data” could contribute to progress in plastic and reconstructive surgery.

Machine Learning Shows Promise in Plastic Surgery Research and Practice

Continue reading “‘Machine learning’ may contribute to new advances in plastic surgery” »

Lookout Silicon Valley — FDA is here. I do suggest tech companies working on technologies that enhances or alters any bio living things to ensure that your certifications, processes are well defined and govern, and in some cases the engineers, etc. will need some level of a medical background and certifications as well. Why many have stated that future engineers and technologists will need a bio background through education, etc.

Helmy Eltoukhy’s company is on a roll. The start-up is a leading contender in the crowded field of firms working on “liquid biopsy” tests that aim to be able to tell in a single blood draw whether a person has cancer.

Venture investors are backing Guardant Health to the tune of nearly $200 million. Leading medical centers are testing its technology. And earlier this month, it presented promising data on how well its screening tool, which works by scanning for tiny DNA fragments shed by dying tumor cells, worked on an initial group of 10,000 patients with late-stage cancers.

Continue reading “There’s a new sheriff in town in Silicon Valley — the FDA” »